Special Issue

Chronic Obstructive Pulmonary Disease (COPD): From Pathophysiology to Novel Therapeutic Approaches

Message from the Guest Editor

This Special Issue aims to showcase the direction of travel in chronic obstructive pulmonary disease (COPD) therapeutics and will accept review articles and original research material on any aspect of COPD pathophysiology or treatment, though preferably with a focus on pathways that may lead to a personalized approach to treatment. Concepts of detailed phenotyping, including radiological, hematological and biochemical markers, treatable traits and targeted therapies have all been raised in recent years in the research literature for COPD. This Special Issue will bring together these themes to illustrate the future landscape for COPD care. Basic, translational and clinical or applied research studies are equally welcome. We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.

Guest Editor

Prof. Dr. Alice M Turner Centre for Translational Inflammation Research, University of Birmingham, Birmingham, UK

Deadline for manuscript submissions

closed (30 November 2021)



Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 5.2 Indexed in PubMed



mdpi.com/si/77695

Biomedicines MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 biomedicines@mdpi.com

mdpi.com/journal/ biomedicines





Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 5.2 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

 Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).